Neuropace financials
$13.94−1.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Gross margin | 77.2% | 73.9% | 73.6% | 71.4% | 74.0% |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | -$36.1M |
| Net margin | −21.5% | −34.0% | −50.4% | −103.4% | −79.9% |
| Diluted EPS | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 |
| EBITDA | -$16.1M | -$21.5M | -$27.0M | -$37.8M | -$23.4M |
| Operating cash flow | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M |
| Diluted shares | 32.7M | 29.1M | 25.9M | 24.6M | 16.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $21.7M | $13.4M | $18.1M | $6.6M | $19.2M |
| Short-term investments | $39.4M | $39.3M | $48.4M | $70.8M | $96.4M |
| Total debt | $58.9M | $59.5M | $57.0M | $52.9M | $49.8M |
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M |
| Shareholders' equity | $19.0M | $8.0M | $20.7M | $34.8M | $73.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology